AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24780069 — intervention group
Group type: EXPERIMENTAL
Intervention: A-C-A-G-T-C haplotype (carrying rs964184-C-allele)
Number of subjects: 1181
Study 24780069 — intervention group
Group type: EXPERIMENTAL
Intervention: Two- to three-locus models
Number of subjects: 1181
Study 22375972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patches (15 mg per 16 hours)
Number of subjects: 1050
Study 22375972 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 1050
Study 20889941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.3%
Number of subjects: 80
Study 20889941 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2%
Number of subjects: 80
Study 20889941 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 18519872 — intervention group
Group type: EXPERIMENTAL
Intervention: istradefylline 20 mg/day
Number of subjects: 395
Study 18519872 — intervention group
Group type: EXPERIMENTAL
Intervention: istradefylline 60 mg/day
Number of subjects: 395
Study 18519872 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 395
Study 15837452 — intervention group
Group type: EXPERIMENTAL
Intervention: One-item measure of mental health status
Number of subjects: 0
Study 15837452 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-item measure of mental health status
Number of subjects: 0
Study 15837452 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliable instruments
Number of subjects: 0
Study 15837452 — intervention group
Group type: EXPERIMENTAL
Intervention: Any valid instrument
Number of subjects: 0
Study 12004017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime-impregnated cement (Group 1, 178 knees)
Number of subjects: 340
Study 12004017 — intervention group
Group type: COMPARATOR
Intervention: Cement without cefuroxime (Group 2, 162 knees)
Number of subjects: 340
Study 12004017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime-impregnated cement (Group 1)
Number of subjects: 340
Study 12004017 — intervention group
Group type: COMPARATOR
Intervention: Cement without cefuroxime (Group 2)
Number of subjects: 340
Study 10090188 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate combined with cyclosporine
Number of subjects: 0
Study 10090188 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate and placebo
Number of subjects: 0
Study 10090188 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus methotrexate plus sulfasalazine
Number of subjects: 0
Study 10090188 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine alone
Number of subjects: 0
Study 10090188 — intervention group
Group type: EXPERIMENTAL
Intervention: AUC summary
Number of subjects: 0
Study 10090188 — intervention group
Group type: COMPARATOR
Intervention: EOS
Number of subjects: 0
Study 7559252 — intervention group
Group type: EXPERIMENTAL
Intervention: External flow resistive mechanical loads (R1/E1, R2/E2)
Number of subjects: 5
Study 7559252 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic mechanical loads (R1/E1, R2/E2)
Number of subjects: 5
Study 7559252 — intervention group
Group type: COMPARATOR
Intervention: Imperceptible loads (R0/E0)
Number of subjects: 5
Study 2140748 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent oral bacterial vaccine
Number of subjects: 34
Study 2140748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 343312 — intervention group
Group type: EXPERIMENTAL
Intervention: Panidazole (1.0 - 2.0 g per day for 6 days)
Number of subjects: 118
Study 343312 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (1.0 - 2.0 g per day for 6 days)
Number of subjects: 118
Study 343312 — intervention group
Group type: EXPERIMENTAL
Intervention: Panidazole (1.0 g per day for 7 days)
Number of subjects: 118
Study 343312 — intervention group
Group type: EXPERIMENTAL
Intervention: Panidazole (1.0 g per day for 10 days)
Number of subjects: 118
Study 31968697 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice including green vegetables five times per week, beef three times per week, 300 mL whole milk per day, and whole dairy butter on bread every day plus standard supportive care.
Number of subjects: 118
Study 31968697 — intervention group
Group type: COMPARATOR
Intervention: Standard supportive care alone.
Number of subjects: 118
Study 31968697 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice group.
Number of subjects: 118
Study 31968697 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 118
Study 30442033 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based navigator intervention
Number of subjects: 179
Study 28432606 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation group (ESG) underwent RCAVF NMES programme
Number of subjects: 36
Study 28432606 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) underwent usual RCAVF forearm exercises
Number of subjects: 36
Study 25774625 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity fast velocity (LIFV) squat protocol (5 × 16 at 40% 1 repetition maximum)
Number of subjects: 17
Study 25774625 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional high-intensity slow velocity (TISV) squat protocol (5 × 8 at 80% 1RM)
Number of subjects: 17
Study 22402673 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 150 mg monthly ibandronate
Number of subjects: 148
Study 22402673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 20605242 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting stent (Infinium, Sahajanand Medical Technologies Pvt Ltd.)
Number of subjects: 13
Study 19186964 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified coronally advanced flap (MCAF) with platelet-rich fibrin (PRF) membrane
Number of subjects: 20
Study 19186964 — intervention group
Group type: COMPARATOR
Intervention: Modified coronally advanced flap (MCAF) alone (control)
Number of subjects: 20
Study 19186964 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified coronally advanced flap (MCAF) with PRF
Number of subjects: 20
Study 17708612 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Yiliu granules (body‐resistance strengthening and tumor‐suppressing granules) with radiotherapy
Number of subjects: 63
Study 17708612 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only
Number of subjects: 63
Study 15570645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg
Number of subjects: 70
Study 15570645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 10 mg
Number of subjects: 70
Study 15570645 — intervention group
Group type: EXPERIMENTAL
Intervention: BASMI (0-2 scoring)
Number of subjects: 70
Study 15570645 — intervention group
Group type: EXPERIMENTAL
Intervention: BASMI (0-10 scoring)
Number of subjects: 70
Study 15570645 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual components of BASMI (cervical rotation, lumbar side flexion)
Number of subjects: 70
Study 15570645 — intervention group
Group type: EXPERIMENTAL
Intervention: BASMI
Number of subjects: 70
Study 11480815 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine (CHX) solution
Number of subjects: 81
Study 11480815 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine (CHX) with fluoride
Number of subjects: 81
Study 11480815 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine (CHX) without fluoride
Number of subjects: 81
Study 11480815 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (ASF) solution
Number of subjects: 81
Study 11480815 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 81
Study 9726723 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg
Number of subjects: 12
Study 9726723 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg
Number of subjects: 12
Study 9726723 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg
Number of subjects: 12
Study 8035399 — intervention group
Group type: EXPERIMENTAL
Intervention: Education only group received a 6-week self-management course.
Number of subjects: 99
Study 8035399 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus physical training group received the course and 6 hours of training.
Number of subjects: 99
Study 8035399 — intervention group
Group type: COMPARATOR
Intervention: Control group received treatment after 3 months.
Number of subjects: 99
Study 8035399 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training group (part of education plus physical training).
Number of subjects: 99
Study 8035399 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects post-intervention.
Number of subjects: 99
Study 2538577 — intervention group
Group type: EXPERIMENTAL
Intervention: CEV regimen (cyclophosphamide 1,000 mg/m2 IV day 1, vincristine 1.4 mg/m2 IV day 1, etoposide 50 mg/m2 IV day 1, followed by etoposide 100 mg/m2/day orally days 2 through 5)
Number of subjects: 353
Study 2538577 — intervention group
Group type: COMPARATOR
Intervention: CAV regimen (cyclophosphamide 1,000 mg/m2 IV day 1, vincristine 1.4 mg/m2 IV day 1, doxorubicin 50 mg/m2 IV day 1)
Number of subjects: 353
Study 2538577 — intervention group
Group type: COMPARATOR
Intervention: CV regimen (cyclophosphamide 2,000 mg/m2 day 1, vincristine 1.4 mg/m2 IV day 1)
Number of subjects: 353
Study 983073 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg pentazocine plus 500 mg acetylsalicylic acid (P + A)
Number of subjects: 10
Study 983073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 983073 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal method (fixed intensity-variable time modification)
Number of subjects: 10
Study 983073 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimuli reaction time measurement
Number of subjects: 10
Study 31157568 — intervention group
Group type: EXPERIMENTAL
Intervention: PREDICT-DM model
Number of subjects: 30000000
Study 26576503 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% VO2peak
Number of subjects: 17
Study 26576503 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% VO2peak
Number of subjects: 17
Study 26576503 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise at 40-60% VO2peak
Number of subjects: 17
Study 26576503 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥80% VO2peak
Number of subjects: 17
Study 26576503 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% to 90% VO2peak
Number of subjects: 17
Study 25916930 — intervention group
Group type: EXPERIMENTAL
Intervention: B-ultrasound monitoring plus gastric insufflation (C)
Number of subjects: 96
Study 25916930 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric insufflation (B)
Number of subjects: 96
Study 25916930 — intervention group
Group type: COMPARATOR
Intervention: Routine (A)
Number of subjects: 96
Study 23389626 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy
Number of subjects: 118
Study 20848671 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback‐assisted PFMT and conventional ES
Number of subjects: 0
Study 20848671 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback‐assisted PFMT and dynamic ES
Number of subjects: 0
Study 20848671 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback‐assisted PFMT
Number of subjects: 0
Study 20848671 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19404176 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified techniques applied to 19 patients (investigational group)
Number of subjects: 39
Study 19404176 — intervention group
Group type: COMPARATOR
Intervention: Standard techniques applied to 20 patients (control group)
Number of subjects: 39
Study 17853049 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 10
Study 14759393 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/day)
Number of subjects: 50
Study 11724948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorophyllin (100 mg, three times a day for 4 months)
Number of subjects: 180
Study 11724948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 9228872 — intervention group
Group type: EXPERIMENTAL
Intervention: Walkabout Orthosis (WO)
Number of subjects: 10
Study 9228872 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocentric Reciprocal Gait Orthosis (IRGO)
Number of subjects: 10
Study 7957525 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU synthetic salmon calcitonin (i.v.)
Number of subjects: 15
Study 3666261 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 100 mg
Number of subjects: 199
Study 3666261 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 75 mg
Number of subjects: 199
Study 29069359 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 14511
Study 29069359 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 14511
Study 29069359 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14511
Study 27383377 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg spironolactone (MR antagonist)
Number of subjects: 71
Study 27383377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 27383377 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 71
Study 26310855 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic (EMLA® or Numby®) plus subcutaneous buffered lidocaine (SQBL)
Number of subjects: 63
Study 26310855 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthetic (EMLA® or Numby®) only
Number of subjects: 63
Study 26310855 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic (EMLA® or Numby®) plus SQBL
Number of subjects: 63
Study 23526241 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg and Aspirin 150 mg capsule (test formulation)
Number of subjects: 80
Study 23526241 — intervention group
Group type: COMPARATOR
Intervention: Lipitor® tablets 10 mg and Nu‐Seals tablets 75 mg (reference formulations)
Number of subjects: 80
Study 19760530 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication and sexual arousal experimental manipulation using erotic film clips
Number of subjects: 0
Study 19760530 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive role‐play videos tailored for measuring risk perception and communication skills
Number of subjects: 0
Study 17709266 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. AG supplementation (0.3 g/kg day from day 4 till 17) and i.v. GH (0.05 mg/kg day divided into 8 boluses, maximum dose at 3 AM, administered on days 7‐17)
Number of subjects: 30
Study 17709266 — intervention group
Group type: COMPARATOR
Intervention: AG and placebo
Number of subjects: 30
Study 17709266 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric isonitrogenous nutrition without AG
Number of subjects: 30
Study 15917338 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA-MMF group
Number of subjects: 151
Study 15917338 — intervention group
Group type: COMPARATOR
Intervention: MMF group
Number of subjects: 151
Study 12891293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (1000 mg/day for 2 days and then 500 mg/day for 5 days, n=19)
Number of subjects: 56
Study 12891293 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg/day for 1 day and then 75 mg/day for 6 days, n=10)
Number of subjects: 56
Study 12891293 — intervention group
Group type: COMPARATOR
Intervention: No ticlopidine (n=18)
Number of subjects: 56
Study 12891293 — intervention group
Group type: COMPARATOR
Intervention: No clopidogrel (n=9)
Number of subjects: 56
Study 15312862 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG during index hospitalization
Number of subjects: 2220
Study 15312862 — intervention group
Group type: COMPARATOR
Intervention: Prior CABG history
Number of subjects: 2220
Study 15312862 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated troponin
Number of subjects: 2220
Study 15312862 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior stable angina
Number of subjects: 2220
Study 15312862 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-segment deviation >or=0.5 mm
Number of subjects: 2220
Study 15312862 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 2220
Study 15312862 — intervention group
Group type: EXPERIMENTAL
Intervention: History of peripheral arterial disease
Number of subjects: 2220
Study 15312862 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score <3.0
Number of subjects: 2220
Study 15312862 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score 3 to 5
Number of subjects: 2220
Study 15312862 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score >5.0
Number of subjects: 2220
Study 15312862 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score association with CABG
Number of subjects: 2220
Study 10440606 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (10-20 mg for 4 weeks)
Number of subjects: 24
Study 10440606 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 4 weeks)
Number of subjects: 24
Study 7849885 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI with spacer
Number of subjects: 152
Study 7849885 — intervention group
Group type: COMPARATOR
Intervention: Nebulizer
Number of subjects: 152
Study 7849885 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 152
Study 2121202 — intervention group
Group type: EXPERIMENTAL
Intervention: CW 200 ventilator
Number of subjects: 20
Study 2121202 — intervention group
Group type: COMPARATOR
Intervention: Nuffield 200 ventilator
Number of subjects: 20
Study 360758 — intervention group
Group type: EXPERIMENTAL
Intervention: XYY men
Number of subjects: 78
Study 360758 — intervention group
Group type: EXPERIMENTAL
Intervention: XXY men
Number of subjects: 78
Study 360758 — intervention group
Group type: COMPARATOR
Intervention: XY men
Number of subjects: 78
Study 30880374 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 needle biopsy with decision analysis approach
Number of subjects: 0
Study 30880374 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer needles
Number of subjects: 0
Study 30880374 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the number of biopsy cores from 10-12 to about 20
Number of subjects: 0
Study 28799216 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical activity intervention
Number of subjects: 1590
Study 28799216 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE) program
Number of subjects: 1590
Study 26205444 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb scaffold
Number of subjects: 501
Study 26205444 — intervention group
Group type: COMPARATOR
Intervention: EES
Number of subjects: 501
Study 23657065 — intervention group
Group type: EXPERIMENTAL
Intervention: QD of 400 mL/min with QB of 200 mL/min
Number of subjects: 12
Study 23657065 — intervention group
Group type: EXPERIMENTAL
Intervention: QD of 400 mL/min with QB of 210 mL/min (condition B')
Number of subjects: 12
Study 23657065 — intervention group
Group type: COMPARATOR
Intervention: QD of 500 mL/min with QB of 200 mL/min (condition A)
Number of subjects: 12
Study 23657065 — intervention group
Group type: COMPARATOR
Intervention: QD of 500 mL/min with QB of 150 mL/min (condition B)
Number of subjects: 12
Study 20959524 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of dexpramipexole (50 mg, 150 mg, or 300 mg)
Number of subjects: 54
Study 20959524 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of dexpramipexole (50 mg twice daily, 100 mg twice daily, or 150 mg twice daily) over 4.5 days
Number of subjects: 54
Study 20959524 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of dexpramipexole
Number of subjects: 54
Study 19840648 — intervention group
Group type: EXPERIMENTAL
Intervention: Excite DSC (n = 20)
Number of subjects: 42
Study 19840648 — intervention group
Group type: EXPERIMENTAL
Intervention: AH‐26 (n = 20)
Number of subjects: 42
Study 19840648 — intervention group
Group type: COMPARATOR
Intervention: Control (no sealer, n = 2)
Number of subjects: 42
Study 16889080 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulone-FS
Number of subjects: 0
Study 16889080 — intervention group
Group type: COMPARATOR
Intervention: Omnik
Number of subjects: 0
Study 14670571 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete callosotomy patients
Number of subjects: 17
Study 14670571 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of visual control in split-brain patients
Number of subjects: 17
Study 14670571 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 17
Study 11406789 — intervention group
Group type: EXPERIMENTAL
Intervention: TiO2-blasted implants
Number of subjects: 50
Study 11406789 — intervention group
Group type: COMPARATOR
Intervention: Machined implants
Number of subjects: 50
Study 8988821 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine + morphine with lidocaine before surgical incision
Number of subjects: 45
Study 8988821 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (group EA)
Number of subjects: 45
Study 8988821 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (group G)
Number of subjects: 45
Study 8988821 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ketamine + morphine with lidocaine after skin incision (group EA)
Number of subjects: 45
Study 8102511 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1600 IU/day)
Number of subjects: 28
Study 8102511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 29793563 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (Group 1)
Number of subjects: 0
Study 29793563 — intervention group
Group type: COMPARATOR
Intervention: Sham (Group 2)
Number of subjects: 0
Study 29793563 — intervention group
Group type: COMPARATOR
Intervention: Control (Group 3)
Number of subjects: 0
Study 27824758 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol‐cervical Foley
Number of subjects: 491
Study 27824758 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley‐oxytocin
Number of subjects: 491
Study 27824758 — intervention group
Group type: COMPARATOR
Intervention: misoprostol alone
Number of subjects: 491
Study 27824758 — intervention group
Group type: COMPARATOR
Intervention: Foley alone
Number of subjects: 491
Study 27824758 — intervention group
Group type: EXPERIMENTAL
Intervention: misoprostol‐Foley
Number of subjects: 491